Skip to main content
. Author manuscript; available in PMC: 2015 Apr 23.
Published in final edited form as: Cancer. 2009 May 15;115(10 0):2346–2354. doi: 10.1002/cncr.24228

Table 1.

Reported Effects of Tyrosine Kinase Inhibitors on VEGF and sVEGFR-2 in Renal Cell Carcinoma Patients

Drug Target VEGF sVEGFR-2 Study
Sorafenib VEGF-1, VEGF-2, VEGF-3, PDGFR, RET, Raf ↑ ↓ Bukowski 20077
Sunitinib VEGF-1, VEGF-2, PDGFR, KIT, RET ↑ ↓ Motzer 200612 Deprimo 200713 George 200721
Axitinib VEGF-1, VEGF-2, VEGF-3, PDGFR, KIT ↑ ↓ Rixe 200519
Pazopanib VEGF-1, VEGF-2, VEGF-3, PDGFR ↑ ↓ Hutson 200818
Cediranib VEGF-1, VEGF-2, VEGF-3, PDGFR, KIT NA ↓ van Herpen 200720

VEGF indicates vascular endothelial growth factor; sVEGFR, soluble vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; NA, not applicable.